AVEO Oncology announces $2 million milestone payment from EUSA Pharma
AVEO Oncology announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma. November 15, 2018